U.S. Intravenous Solutions Market to Surpass US$ 4,385.7 Million by 2027, At a CAGR of 6.4% | Coherent Market Insights
SEATTLE, May 04, 2021, (PHARMIWEB) –
Every other hospitalised woman, according to many study experts, needs IV remedies. The growing number of hospitals in the United States, as well as the hospitalisation rates, are projected to fuel growth in the IV solutions market in the near future. As per the American Hospital Association, the number of hospitals in the U.S. rose to 6,210 in 2019 from 5,534 in 2018, in order to satisfy the patient population’s treatment needs.
In addition, as per the American Hospital Association 2019, gross hospital admissions in January 2019 were 36,510,207, up from 35,158,934 in January 2018, a 3.4 percent rise.
To learn more about this report, request a sample copy*
* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy of this report @ https://www.coherentmarketinsights.com/insight/request-sample/3400
Moreover, due to the involvement of major companies such as Baxter International Inc. and ICU Medical, Inc. in the region, the U.S. intravenous solutions market is projected to expand significantly.
Increasing prevalence of diarrhea is expected to drive the U.S. intravenous solutions market growth during the forecast period. For instance, according to University of Texas Health Science Center 2014, around 179 million cases of acute diarrhea occur each year in the U.S. and most of those cases are entirely preventable. The main causes of diarrheal infections include norovirus outbreak and foodborne pathogens, with most infections stemming from contaminated leafy green vegetables.
However, increasing shortage of IV solutions in the U.S. is one of the factors that is expected to hinder growth of the market. Due to hurricane strike in Puerto Rico in 2017, the U.S. witnessed shortage of IV. This is owing to Puerto Rico being one of the major producers of IV bags. The U.S government is still working on ways to regain the production of IV fluids to meet the rising demand for IV fluids in the U.S.
The U.S. intravenous solutions market is projected to grow at a CAGR of 6.4 percent from 2019 to 2027, owing to an increase in hospitals and hospitalisation rates.
The saline solution group, which is a combination of sodium chloride in water and used as an intravenous solution for managing hypertension, gastroenteritis, and diabetic ketoacidosis, is anticipated to hold the largest market share share in 2027.
Baxter International Inc., ICU Medical, Inc., B. Braun Melsungen AG, and Grifols, S.A. are among the major players in the U.S. intravenous solutions market.
Buy This Complete A Business Report: https://www.coherentmarketinsights.com/insight/buy-now/3400
By Solution Type:
- Normal Saline (0.9% NaCl)
- Hypertonic Saline
- Lactated Ringer’s
- Amino Acid
- Vitamins & Minerals
- Heparin and Trace Elements
- Mixed Solutions
By Bag Type:
- Large Volume Bags (greater than 250ml)
- Small Volume Bags (less than 250ml)
By Application Type:
- Basic IV Solution
- Nutritional IV Solution
- Blood IV Solution
- Drug IV Solution
- Irrigation IV Solution
By End User:
- Ambulatory Surgery Centers
- Home Care Settings
View Press Release For More Information @ https://www.coherentmarketinsights.com/press-release/us-intravenous-solution-market-2763
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Coherent Market Insights,
1001 4th Ave,
#3200 Seattle, WA 98154, U.S.
Phone: US +1-206-701-6702/UK +44-020 8133 4027
- CDN Newswire